Mui Kow - Haw Par Executive
| HAWPY Stock | USD 28.64 0.00 0.00% |
Executive
Mr. Kow Mui Lick is Senior Manager Quality Regulatory Affairs of Healthcare of Haw Par Corporation Ltd. He joined Haw Par Healthcare in 1991 as QCLaboratory Manager and promoted to Senior Manager in 2007. Appointed to present position in 2011. Holds a BS from the University of Singapore.
| Phone | 65 6337 9102 |
| Web | https://www.hawpar.com |
Haw Par Management Efficiency
Haw Par's management efficiency ratios could be used to measure how well Haw Par manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Andrin Oswald | Novartis AG ADR | 41 | |
| Susan MD | AstraZeneca PLC ADR | 58 | |
| Linda MD | Novartis AG ADR | 61 | |
| Mikael MD | Pfizer Inc | 66 | |
| Jeffrey George | Novartis AG ADR | 41 | |
| Ye Liu | Santen Pharmaceutical Co | N/A | |
| Vicente Torre | Grifols SA ADR | 63 | |
| Charles Sawyers | Novartis AG ADR | 62 | |
| Noriaki Yamamoto | Santen Pharmaceutical Co | N/A | |
| Gottlieb Keller | Roche Holding Ltd | 64 | |
| Montserrat Calvo | Grifols SA ADR | N/A | |
| Samir Shah | Novartis AG ADR | N/A | |
| Richard Francis | Novartis AG ADR | 50 | |
| Alan Hippe | Roche Holding Ltd | 56 | |
| Masamichi Sato | Santen Pharmaceutical Co | N/A | |
| Vasant Narasimhan | Novartis AG ADR | 48 | |
| Ko Takahashi | Santen Pharmaceutical Co | N/A | |
| Susanne Fiedler | Organon Co | 56 | |
| Cristina Wilbur | Roche Holding Ltd | 56 | |
| Karenann Terrell | GSK plc | 56 | |
| Jennifer Halchak | Organon Co | N/A | |
Management Performance
| Return On Equity | 0.0424 | |||
| Return On Asset | 0.0063 |
Haw Par Leadership Team
Elected by the shareholders, the Haw Par's board of directors comprises two types of representatives: Haw Par inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Haw. The board's role is to monitor Haw Par's management team and ensure that shareholders' interests are well served. Haw Par's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Haw Par's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sat Khattar, Independent Director | ||
| Siew Shiu, Acting Group Internal Audit Manager | ||
| Meng Kwek, Regional General Manager of Underwater World Singapore Pte Ltd / Haw Par Leisure Pte Ltd | ||
| Swee Sim, Non-Executive Independent Director | ||
| Cho Wee, Non-Executive, Non Independent Chairman of the Board | ||
| Chua Keeth, Deputy General Manager - Marketing of Haw Par Healthcare Limited | ||
| Wah Ng, Deputy General Manager-Manufacturing of Healthcare | ||
| Ee Wee, CEO and President Director, Member of Investment Committee, CEO of Haw Par Healthcare Limited and Acting President of Haw Par Healthcare Limited | ||
| Mui Kow, Senior Manager-Quality & Regulatory Affairs of Healthcare | ||
| Brian Loo, Group Mang | ||
| Peter Chew, Deputy General Manager of Underwater World Singapore Pte Ltd | ||
| Kia Chew, Non-Executive Independent Director | ||
| Choon Chew, Non-Executive Independent Director | ||
| Tang Lee, Mang Communications | ||
| Tang Chow, Human Director | ||
| Anthony Chang, Curator of Underwater World Singapore Pte Ltd | ||
| Suan Lee, Non-Executive Independent Director | ||
| Kun Chiew, Group Sec | ||
| Ah Han, Executive Director, Member of Investment Committee, General Manager of Haw Par Healthcare Limited and Director of Haw Par Healthcare Limited | ||
| Hiang Gn, Non-Executive Independent Director | ||
| Seok Lim, CFO and Company Secretary | ||
| Sien Tarn, General Manager - Corporate Development & Property Division | ||
| Sung Whang, General Manager of Underwater World Pattaya Ltd | ||
| Soo Hwang, Non-Executive Independent Director | ||
| Bee Goh, Director & General Manager - Manufacturing of Haw Par Healthcare Limited | ||
| Eechao Wee, Non-Executive Non Independent Director | ||
| Say Chow, Group Finance Controller | ||
| Jasmin Hong, Deputy General Manager - Marketing of Haw Par Healthcare Limited | ||
| Kay Lee, Company Secretary |
Haw Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Haw Par a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0424 | |||
| Return On Asset | 0.0063 | |||
| Profit Margin | 0.79 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | (701.58 M) | |||
| Shares Outstanding | 55.34 M | |||
| Price To Earning | 21.33 X | |||
| Price To Book | 0.73 X | |||
| Price To Sales | 10.01 X | |||
| Revenue | 141.18 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haw Par. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Haw Pink Sheet analysis
When running Haw Par's price analysis, check to measure Haw Par's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haw Par is operating at the current time. Most of Haw Par's value examination focuses on studying past and present price action to predict the probability of Haw Par's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haw Par's price. Additionally, you may evaluate how the addition of Haw Par to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |